CN101272776B - 氨基甲酸酯在制备治疗物质滥用相关疾病药物中的用途 - Google Patents

氨基甲酸酯在制备治疗物质滥用相关疾病药物中的用途 Download PDF

Info

Publication number
CN101272776B
CN101272776B CN200580051664XA CN200580051664A CN101272776B CN 101272776 B CN101272776 B CN 101272776B CN 200580051664X A CN200580051664X A CN 200580051664XA CN 200580051664 A CN200580051664 A CN 200580051664A CN 101272776 B CN101272776 B CN 101272776B
Authority
CN
China
Prior art keywords
formula
enantiomer
enantiomers
mixture
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200580051664XA
Other languages
English (en)
Chinese (zh)
Other versions
CN101272776A (zh
Inventor
C·R·普拉塔-萨拉曼
B·赵
R·E·特怀曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN101272776A publication Critical patent/CN101272776A/zh
Application granted granted Critical
Publication of CN101272776B publication Critical patent/CN101272776B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN200580051664XA 2005-07-26 2005-07-26 氨基甲酸酯在制备治疗物质滥用相关疾病药物中的用途 Expired - Fee Related CN101272776B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/026439 WO2007018496A1 (en) 2005-07-26 2005-07-26 Methods for treating substance-related disorders

Publications (2)

Publication Number Publication Date
CN101272776A CN101272776A (zh) 2008-09-24
CN101272776B true CN101272776B (zh) 2012-10-03

Family

ID=35064669

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200580051664XA Expired - Fee Related CN101272776B (zh) 2005-07-26 2005-07-26 氨基甲酸酯在制备治疗物质滥用相关疾病药物中的用途

Country Status (13)

Country Link
EP (1) EP1928451B1 (enExample)
JP (1) JP5094720B2 (enExample)
KR (1) KR101199499B1 (enExample)
CN (1) CN101272776B (enExample)
AT (1) ATE538784T1 (enExample)
AU (1) AU2005335241B9 (enExample)
BR (1) BRPI0520451A2 (enExample)
CA (1) CA2616721C (enExample)
EA (1) EA019935B1 (enExample)
ES (1) ES2385087T3 (enExample)
IL (1) IL189003A0 (enExample)
NO (1) NO20080877L (enExample)
WO (1) WO2007018496A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1890684T3 (pl) 2005-06-08 2014-05-30 Sk Biopharmaceuticals Co Ltd Leczenie zaburzeń snu i czuwania
WO2011005473A2 (en) 2009-06-22 2011-01-13 Shionogi Pharma, Inc. Methods for treating or preventing fatigue
US8232315B2 (en) * 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
ES2447295T3 (es) 2009-11-06 2014-03-11 Sk Biopharmaceuticals Co., Ltd. Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad
RU2557533C2 (ru) 2009-11-06 2015-07-20 Ск Биофармасъютиклс Ко., Лтд. Способы лечения синдрома фибромиалгии
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
BR112015022197B1 (pt) 2013-03-13 2022-06-07 Sk Biopharmaceuticals Co., Ltd. Uso de um composto para o tratamento de cataplexia
CN105873576B (zh) 2013-07-18 2019-07-19 爵士制药国际Iii有限公司 治疗肥胖
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
KR20240162165A (ko) 2017-06-02 2024-11-14 재즈 파마슈티칼즈 아일랜드 리미티드 과다 졸림증을 치료하기 위한 방법 및 조성물
JP7257091B2 (ja) * 2019-06-27 2023-04-13 沼澤 敏彦 認知症の治療及び予防薬
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
CN1503666A (zh) * 2001-02-27 2004-06-09 ����-������ҩƷ��˾ 用于预防或治疗双相性精神障碍的氨基甲酸酯化合物
CN1503667A (zh) * 2001-02-27 2004-06-09 ����-������ҩƷ��˾ 用于预防或治疗神经变性疾病的氨基甲酸酯化合物
CN1505507A (zh) * 2001-02-27 2004-06-16 ����-������ҩƷ��˾ 用于预防或治疗精神病的氨基甲酸酯化合物
CN1505508A (zh) * 2001-02-27 2004-06-16 ����-������ҩƷ��˾ 用于预防或治疗运动障碍的氨基甲酸酯化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
CN1503666A (zh) * 2001-02-27 2004-06-09 ����-������ҩƷ��˾ 用于预防或治疗双相性精神障碍的氨基甲酸酯化合物
CN1503667A (zh) * 2001-02-27 2004-06-09 ����-������ҩƷ��˾ 用于预防或治疗神经变性疾病的氨基甲酸酯化合物
CN1505507A (zh) * 2001-02-27 2004-06-16 ����-������ҩƷ��˾ 用于预防或治疗精神病的氨基甲酸酯化合物
CN1505508A (zh) * 2001-02-27 2004-06-16 ����-������ҩƷ��˾ 用于预防或治疗运动障碍的氨基甲酸酯化合物

Also Published As

Publication number Publication date
AU2005335241A1 (en) 2007-02-15
ATE538784T1 (de) 2012-01-15
EP1928451A1 (en) 2008-06-11
AU2005335241B2 (en) 2012-11-15
JP2009502914A (ja) 2009-01-29
IL189003A0 (en) 2008-11-03
NO20080877L (no) 2008-02-19
BRPI0520451A2 (pt) 2009-05-12
EP1928451B1 (en) 2011-12-28
EA019935B1 (ru) 2014-07-30
KR20080037055A (ko) 2008-04-29
ES2385087T3 (es) 2012-07-18
WO2007018496A1 (en) 2007-02-15
JP5094720B2 (ja) 2012-12-12
EA200800422A1 (ru) 2008-10-30
KR101199499B1 (ko) 2012-11-09
AU2005335241B9 (en) 2012-12-20
CA2616721A1 (en) 2007-02-15
CN101272776A (zh) 2008-09-24
CA2616721C (en) 2014-01-21

Similar Documents

Publication Publication Date Title
TWI483719B (zh) 用於治療藥物成癮及改善與藥物成癮相關的行為之組成物
JP5901528B2 (ja) 線維筋痛症候群の治療方法
CN101272776B (zh) 氨基甲酸酯在制备治疗物质滥用相关疾病药物中的用途
KR100858232B1 (ko) 카바메이트 화합물을 포함하는 거동 장애 예방 또는 치료용 약제학적 조성물
CN101472571B (zh) 毒蕈碱型受体m1拮抗剂在制备治疗心理学病况药物中的应用
RU2477634C2 (ru) Лечение психологических состояний с применением антагонистов m1-мускариновых рецепторов
NZ565188A (en) The use of carbamate derivatives to treat drug withdrawal disorders
HK1209058B (en) Compositions for treating drug addiction and improving addiction-related behavior
JP2023505054A (ja) 処置方法
HK1176285B (en) Compositions for treating drug addiction and improving addiction-related behavior
HK1063435A1 (en) Carbamate compounds for use in preventing or treating neuropathic pain
NZ718978A (en) Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20180102

Address after: Rui Lin cave of Zhong Lu District, Seoul, South Korea 99

Patentee after: SK BIOPHARMACEUTICALS Co.,Ltd.

Address before: Beals Belgium

Patentee before: JANSSEN PHARMACEUTICA N.V.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121003

CF01 Termination of patent right due to non-payment of annual fee